Helicobacter pylori
Conditions
Interventions
Keverprazan combined with low-dose amoxicillin group:Keverprazan 20 mg twice daily (bid) plus amoxicillin 1000 mg twice daily (bid)
Keverprazan combined with high-dose amoxicillin group:Keverprazan 20 mg twice daily (bid) plus amoxicillin 1000 mg three times daily (tid)
Sponsors
Northern Jiangsu People's Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged>= 60 years; 2.Patients with Helicobacter pylori (H. pylori) infection diagnosed by ¹³C/¹4C urea breath test (UBT) or rapid urease test (RUT); 3. Regardless of previous history of H. pylori eradication therapy; 4.Provision of informed consent and voluntary participation in the study.
Exclusion criteria
Exclusion criteria: 1. Individuals who are allergic to the study medication; 2.Those who have used antibiotics, bismuth preparations, and probiotics in the past 4 weeks or potassium-competitive acid blockers (P-CABs), proton pump inhibitors (PPIs), or H2-receptor antagonists in the past 2 weeks; 3. Patients complicated by severe diseases of the heart, liver, lungs, kidneys, or other vital organs, as well as those with immunocompromise; 4. Current pregnancy, lactation, or pregnancy planning; 5. Patients with concomitant gastrointestinal malignancy, or a history of esophageal or gastric surgery; 6. Patients unable to cooperate with the study due to alcoholism, substance abuse, severe mental illness, or other relevant conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Compliance; | — |
Countries
China
Contacts
Public ContactBengang Zhou
Northern Jiangsu People's Hospital
Outcome results
None listed